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Abstract
Healthcare-associated pneumonia (HCAP) includes a broad spectrum of patients who acquire pneumonia through outpatient contact
with the health system. Although limited prospective data exist, it has been suggested that all patients with HCAP should receive empir-
ical therapy with a multidrug regimen directed against drug-resistant organisms. We aimed to determine the differences in aetiology and
outcomes between HCAP groups and a community-acquired pneumonia (CAP) group, and to assess the presence of antibiotic-resistant
bacteria. All consecutive non-immunocompromised adults hospitalized with pneumonia were prospectively included from 2001 to 2009.
Patients who had had recent contact with the health system through nursing homes, home healthcare programmes, haemodialysis clinics
or prior hospitalization were considered to have HCAP. A total of 2245 patients with pneumonia were hospitalized through the
emergency room, of whom 577 (25.7%) had HCAP. Signiﬁcant differences in causative pathogens were found between groups. Anti-
biotic-resistant organisms, including methicillin-resistant Staphylococcus aureus, resistant strains of Pseudomonas aeruginosa, and extended-
spectrum b-lactamase-producing Enterobacteriaceae, were scarce in all groups. In contrast, aspiration pneumonia was particularly
frequent. No differences were found regarding inappropriate initial empirical antibiotic therapy between groups. Overall mortality was
higher in patients who attended a hospital or haemodialysis clinic or received intravenous chemotherapy in the 30 days before pneumo-
nia, and among patients who resided in a nursing home or long-term-care facility. In conclusion, most HCAP patients could be treated
in the same way as patients with CAP, after carefully ruling out the presence of aspiration pneumonia.
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Introduction
Healthcare-associated pneumonia (HCAP) has been recog-
nized as a new category of respiratory infection that includes
pneumonia acquired through recent outpatient contact with
the health system [1,2]. It has been suggested that HCAP
merits a distinct therapeutic approach, because its epidemiol-
ogy, causative organisms and antibiotic susceptibilities may
differ from those of community-acquired pneumonia (CAP).
Although limited prospective data exist, some studies have
found that the HCAP population is at increased risk of infec-
tion with antibiotic-resistant organisms and that initial inade-
quate antibiotic coverage increases the mortality rate [2–5].
In this setting, the initial recommendation in the American
Thoracic Society/Infectious Diseases Society of America
guidelines for HCAP treatment stated that all patients with
HCAP criteria should receive empirical therapy with a multi-
drug regimen directed against drug-resistant microorganisms
[1]. However, different subgroups of HCAP patients include
those with varying severity of illness and reasons for having
contact with the healthcare environment [2–6]. This broad
spectrum of populations may present differences in terms of
epidemiology and patient-speciﬁc risks for antibiotic-resistant
pathogens [7,8]. Therefore, multidrug regimens may not
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always be needed and may lead to antibiotic overuse, thus
potentially stimulating the development of antimicrobial resis-
tance and adverse events, and increasing cost. Recently, it
has been suggested that the concept of HCAP is in need of
revision [9,10]. With this purpose in mind, we conducted a
prospective study to determine the differences in aetiology
and outcome between HCAP groups and a CAP group, and
to assess the presence of antibiotic-resistant organisms in a
large prospective cohort of patients.
Materials and Methods
Study subjects and design
The study was carried out in a 900-bed university hospital
for adults. All non-severely immunosuppressed patients
admitted to hospital with pneumonia through the emergency
department from 1 January 2001 to 31 October 2009 were
prospectively recruited and followed up. Patients with immu-
nosuppression (neutropenia, AIDS, transplantation, and
chronic corticosteroid treatment) were not included.
Patients were classiﬁed as having HCAP as previously
described [2,11]. Accordingly, they had to fulﬁll one of the
following criteria:
1. Group 1: received any intravenous therapy at home;
received wound care or specialized nursing care through
a healthcare agency, family, or friends; or had self-admin-
istered intravenous medical therapy in the 30 days
before pneumonia (patients whose only home therapy
was oxygen were excluded).
2. Group 2: attended a hospital or haemodialysis clinic or
received intravenous chemotherapy in the 30 days
before pneumonia.
3. Group 3: admitted to an acute-care hospital for two or
more days in the 90 days before pneumonia.
4. Group 4: resided in a nursing home or long-term-care
facility.
Patients who fulﬁlled more than one criterion for HCAP
were excluded from the general analysis, but the aetiology
of these pneumonias was examined. Patients were placed
in the CAP group if they did not meet the criteria for
HCAP. One hundred and twenty-six patients with HCAP
documented between 2001 and 2004 were the subject of
another investigation by our group [2]. The high number
of patients included allowed us to analyse cases according
to how they fulﬁlled the deﬁnition of HCAP. Thus, for the
purposes of the present study, we compared aetiology and
outcomes in each speciﬁc HCAP group and in the CAP
group.
This prospective, longitudinal and observational study was
approved by the institutional review board.
Microbiological studies
Microbiological studies included two sets of blood samples
and, when available, a sputum Gram stain and culture.
Urinary antigen detection for Streptococcus pneumoniae and
Legionella pneumophila serogroup 1 was performed if indi-
cated by the attending physician. Paired serum samples
obtained during the acute and convalescent phases of infec-
tion (separated by a 3–8-week interval) were also obtained
for serological studies.
The investigation of pathogens in blood, normally sterile
ﬂuids, sputum and other samples was performed with
standard microbiological procedures. Sputum specimens
were usually collected under the supervision of a resident
or nurse before antibiotic therapy was begun. Specimens
were sent to the laboratory and processed immediately.
No special procedures were performed to obtain sputum
samples if they could not be obtained spontaneously. A
Gram stain was performed on a purulent portion of each
sputum specimen and examined by trained personnel. The
slides were evaluated for quality under low magniﬁcation
(·10). Salivary contamination was detected by noting the
presence of squamous epithelial cells, and purulence was
determined by noting the presence of polymorphonuclear
cells. Sputum samples were considered to be of good
quality if they had <10 squamous cells and >25 leukocytes
per low-power ﬁeld. Otherwise, the sputum sample was
considered to be contaminated by saliva and rejected.
Good-quality specimens were then screened for a predom-
inant bacterial morphological type in an oil immersion ﬁeld
(·100). Sputum cultures were processed immediately in
blood agar, chocolate agar and MacConkey agar media.
Isolation of L. pneumophila was also attempted by the use
of buffered charcoal–yeast extract medium in selected
cases.
The S. pneumoniae antigen in urine was detected by use
of a rapid immunochromatographic assay (NowTM; Binax,
Portland, ME, USA). L. pneumophila serogroup I antigen in
urine was detected with an immunochromatographic
method (NOW Legionella Urinary Antigen Test; Binax) or
ELISA (ELISA-Bartels; Bartels, Trinity Biotech, Wicklow,
Ireland). The antibiotic sensitivities of all isolates were
determined with a microdilution panel (STRHAEl, Sensiti-
tre; Trek Diagnostic Systems, East Grinstead, UK), accord-
ing to the NCCLS guidelines [12,13]. To stratify patients
into risk classes, we used the prediction rule, calculated
according to the pneumonia severity index, as described
elsewhere [14].
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Deﬁnitions
Pneumonia was deﬁned as the presence of a new inﬁltrate
on chest radiography plus at least one of the following: fever
(temperature ‡38.0C) or hypothermia (temperature
£35.0C), new cough with or without sputum production,
pleuritic chest pain, dyspnoea, or altered breath sounds on
auscultation. Aspiration pneumonia was diagnosed on a clini-
cal and radiological basis in patients who had risk factors
such as compromised consciousness, altered gag reﬂex, dys-
phagia, severe periodontal disease, putrid sputum, and radio-
graphic evidence of involvement of a dependent pulmonary
segment or necrotizing pneumonia.
Antibiotic therapy was administered in the emergency
department according to the hospital guidelines, as previ-
ously reported [2]. Initial inappropriate therapy was deﬁned
as the absence of antimicrobial agents directed at a speciﬁc
type of organism or administration of an antibiotic to which
the organism was resistant. The appropriateness of antibiotic
therapy was analysed for all cases with an aetiological diagno-
sis according to susceptibility test criteria, as previously
described [15]. Patients with aspiration pneumonia who had
not received anaerobic coverage (i.e. amoxycillin–clavulanate)
were considered to have received inappropriate empirical
antibiotic therapy.
Methicillin-resistant Staphylococcus aureus, resistant strains
of Pseudomonas aeruginosa, extended-spectrum b-lactamase-
producing Enterobacteriaceae and other non-fermenting
Gram-negative bacilli were considered to be antibiotic-
resistant organisms.
The early case-fatality rate was deﬁned as death resulting
from any cause within 48 h of hospitalization. The overall
case-fatality rate was deﬁned as death resulting from any
cause within 30 days of hospitalization.
Statistical analysis
To detect signiﬁcant differences between groups, we used the
Fisher exact test for categorical variables, and the two-tailed
t-test, ANOVA or Mann–Whitney test for continuous vari-
ables, when appropriate. Statistical signiﬁcance was established
at a = 0.05. All reported p-values are two-tailed. The results
were analysed with a commercially available statistical soft-
ware package (SPSS, version 11.5; SPSS, Chicago, IL, USA).
Results
During the study period, 2245 consecutive patients were
analysed, of whom 1668 (74.3%) had CAP and 577 (25.7%)
had HCAP. Ninety-two (4.1%) patients fulﬁlled more than
one criterion for HCAP and were excluded from the general
analysis. Of the remaining 485 HCAP patients, 19 (0.8%)
were included in group 1, 198 (8.8%) in group 2, 137 (6.1%)
in group 3, and 131 (5.8%) in group 4.
The demographic and clinical characteristics of patients
by epidemiological group are detailed in Table 1. Patients
with CAP were younger than patients with HCAP (64.9 vs.
72.2 years; 95% CI of mean difference 5.8–8.8 years).
Patients in HCAP group 4 were older than those in the
other groups. Comorbid conditions were signiﬁcantly more
frequent in HCAP patients. Speciﬁcally, cancer was more
frequent in groups 1 and 3, chronic renal disease in
group 2, chronic obstructive pulmonary disease in groups 2,
3 and 4, chronic liver disease in group 3, and cerebrovascu-
lar disease and dementia in group 4. Moreover, patients
included in group 4 presented speciﬁc clinical characteris-
tics: they were less frequently current smokers and heavy
alcohol drinkers, and had more commonly been vaccinated
against inﬂuenza. Additionally, they were more frequently
classiﬁed into high-risk pneumonia severity index classes,
and were more likely to present impaired consciousness,
respiratory failure and septic shock at admission than the
remaining patients.
The description of microbial assessment is detailed in
Table 2. An aetiological diagnosis was more frequently estab-
lished in patients in group 4 than in the other groups.
Table 3 shows the distribution of causative organisms in all
groups. Overall, S. pneumoniae was the most frequent causa-
tive pathogen. Signiﬁcant differences in aetiology were docu-
mented between groups: L. pneumophila was more frequent
in the CAP group, Staphylococcus aureus was more common
in group 1, and aspiration pneumonia was more frequent in
group 4. Patients who fulﬁlled more than one criterion for
HCAP had pneumococcal pneumonia (30.4% vs. 41.1%;
p 0.04) and pneumonia caused by Legionella (0% vs. 6.7%;
p 0.003) less commonly than patients with CAP. Conversely,
aspiration pneumonia (31.5% vs. 5.5%; p <0.001) and bacte-
raemic P. aeruginosa pneumonia (2.2% vs. 0.3%; p 0.04) were
more frequent in this population.
Regarding S. pneumoniae isolates, penicillin resistance rates
were as follows: 7.3% in the CAP group, 0% in group 1,
7.7% in group 2, 4.2% in group 3, 13.3% in group 4, and
28.6% in patients who fulﬁlled more than one criterion for
HCAP (no signiﬁcant differences). Erythromycin resistance
was more frequent in group 4 (15.6% in the CAP group, 0%
in group 1, p 0.96; 23.1% in group 2, p 0.40; 16.7% in
group 3, p 0.77; 40% in group 4, p 0.02; and 28.6% in
patients who fulﬁlled more than one criterion for HCAP,
p 0.31). Only one pneumococcal strain isolated from a
patient with CAP was resistant to levoﬂoxacin (MIC, 16 mg/
L). Among Haemophilus inﬂuenzae strains, no signiﬁcant
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differences in the prevalence of b-lactamase production
were detected between groups. Methicillin-resistant Staphylo-
coccus aureus was isolated in only two cases (from a patient
with CAP and from a patient who fulﬁlled more than one
criterion for HCAP). Two strains of P. aeruginosa were
multidrug-resistant. No Gram-negative bacilli produced
extended-spectrum b-lactamases.
Most patients received adequate initial empirical antibiotic
therapy (Table 4). Patients in group 4 more frequently
received antibiotic monotherapy, mainly amoxycillin–clavula-
nate. No differences were found regarding inappropriate ini-
tial empirical therapy between groups. The aetiology of
pneumonia among patients receiving inappropriate initial
antibiotic therapy was as follows: aspiration pneumonia (21
TABLE 2. Microbiological diagnosis of pneumonia
Characteristic
CAP HCAP
Group 1a Group 2a Group 3a Group 4a
n = 1668,
no. (%)
n = 19,
no. (%) p
n = 198,
no. (%) p
n = 137,
no. (%) p
n = 131,
no. (%) p
Gram stain and sputum culture 358 (21.5) 8 (42.1) 0.03 45 (22.7) 0.75 35 (25.5) 0.26 34 (25.9) 0.23
Blood cultures 199 (11.9) 1 (5.2) 0.77 30 (15.2) 0.23 11 (8.0) 0.22 16 (12.2) 0.92
Pleural ﬂuid culture 67 (4.0) 0 (0) 1.00 4 (2.0) 0.23 6 (4.4) 0.98 5 (3.8) 0.91
Urinary antigen test 520 (31.2) 8 (42.1) 0.44 67 (33.8) 0.17 39 (28.5) 0.73 42 (32.1) 0.83
Serology 70 (4.2) 0 (0) 1.00 5 (2.5) 0.27 0 (0) 0.01 3 (2.3) 0.29
CAP, community-acquired pneumonia; HCAP, healthcare-associated CAP.
aMore than one positive test result: 148 (8.9%) patients in the CAP group, ﬁve (26%) patients in group 1, 28 (14.1%) patients in group 2, six (4.3%) patients in group 3, and
four (3%) patients in group 4.
TABLE 1. Main demographic and clinical characteristics by epidemiological groupa
Characteristic
CAP HCAP
Group 1b Group 2b Group 3b Group 4b
n = 1668,
no. (%)
n = 19,
no. (%) p
n = 198,
no. (%) p
n = 137,
no. (%) p
n = 131,
no. (%) p
Demographics
Age (years) (mean (SD)) 64.9 (17.2) 67.7 (14.2) 0.67 70.6 (13.8) <0.001 69.8 (13.5) <0.001 77.8 (15.2) <0.001
Male sex 1152 (69.1) 14 (73.7) 0.66 137 (69.2) 0.97 99 (72.3) 0.43 70 (53.4) <0.001
Current smoker 449 (27.1) 4 (21.1) 0.55 43 (21.8) 0.11 32 (23.5) 0.36 7 (5.4) <0.001
Heavy drinking 305 (18.4) 4 (21.1) 0.76 41 (20.8) 0.41 24 (17.6) 0.82 5 (3.9) <0.001
Vaccination status
Inﬂuenza vaccine (season) 711 (47.5) 11 (64.7) 0.15 104 (60.5) 0.001 71 (62.3) 0.002 73 (72.3) <0.001
Pneumococcal vaccinationc 301 (20.6) 4 (22.2) 0.77 43 (26.5) 0.08 40 (36.7) <0.001 22 (25.6) 0.27
Underlying disease 1226 (73.5) 19 (100) 0.006 182 (91.9) <0.001 127 (92.7) <0.001 116 (88.5) <0.001
COPD 437 (26.2) 6 (31.6) 0.60 65 (32.8) 0.04 70 (51.1) <0.001 23 (17.6) 0.02
Diabetes mellitus 356 (21.3) 4 (21.1) 1 53 (26.8) 0.08 35 (25.5) 0.25 37 (28.2) 0.06
Cancer 128 (7.7) 5 (26.3) 0.01 23 (11.6) 0.05 24 (17.5) <0.001 11 (8.4) 0.76
Cerebrovascular disease 137 (8.2) 1 (5.3) 1 33 (16.7) <0.001 22 (16.1) 0.002 36 (27.5) <0.001
Chronic heart disease 395 (23.7) 7 (36.8) 0.18 69 (34.8) 0.001 46 (33.6) 0.01 36 (27.5) 0.32
Chronic renal disease 91 (5.5) 1 (5.3) 1 52 (26.3) <0.001 12 (8.8) 0.10 9 (6.9) 0.49
Chronic liver disease 99 (5.9) 2 (10.5) 0.31 17 (8.6) 0.14 16 (11.7) 0.008 6 (4.6) 0.52
Dementia 54 (3.2) 1 (5.3) 0.46 10 (5.1) 0.21 3 (2.2) 0.79 49 (37.4) <0.001
Prior antibiotic therapy (3 months) 153 (9.5) 5 (29.4) 0.01 54 (29.5) 0.01 55 (43) <0.001 24 (20.5) <0.001
High severity risk PSI class (IV–V) 915 (55) 10 (52.6) 0.83 138 (69.7) <0.001 105 (77.2) <0.001 121 (93.1) <0.001
Clinical features
Altered mental status on admission 210 (12.6) 2 (10.5) 1 35 (17.5) 0.04 14 (10.2) 0.41 50 (38.5) <0.001
Renal failure (Cr >150 mM) 277 (16.7) 3 (15.8) 1 66 (33.7) <0.001 19 (14.1) 0.43 24 (18.3) 0.63
Respiratory failure (PO2/FIO2 <300
or saturation <90%)
935 (77.4) 11 (84.6) 0.74 114 (78.6) 0.73 87 (79.1) 0.68 91 (91) 0.001
Multilobar inﬁltrates 530 (32) 6 (33.3) 0.90 59 (30.1) 0.58 43 (31.9) 0.96 54 (41.5) 0.02
Shock at admission 140 (8.4) 1 (5.3) 1 19 (9.6) 0.57 12 (8.8) 0.89 23 (17.7) <0.001
Pleural effusion 302 (18.2) 5 (26.3) 0.36 31 (15.7) 0.37 21 (15.4) 0.42 19 (14.5) 0.28
Bacteraemia 204 (12.5) 1 (5.9) 0.71 27 (13.8) 0.62 14 (10.5) 0.50 18 (14.1) 0.61
CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; Cr, creatinine; HCAP, healthcare-associated CAP; PSI, pneumonia severity index; SD,
standard deviation.
aData are given as numbers (percentages), except where otherwise indicated.
bGroup 1: received intravenous therapy at home; received wound care or specialized nursing care through a healthcare agency, family, or friends; or had self-administered
intravenous medical therapy in the 30 days before pneumonia (patients whose only home therapy was oxygen were excluded). Group 2: attended a hospital or haemodialysis
clinic or received intravenous chemotherapy in the 30 days before pneumonia. Group 3: admitted to an acute-care hospital for two or more days in the 90 days before pneu-
monia. Group 4: resided in a nursing home or long-term-care facility. p-Values show the differences between the HCAP and CAP groups.
cPneumococcal vaccination (<5 years).
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cases), Gram-negative bacilli (16), atypical agents (15),
L. pneumophila (12) and S. pneumoniae (1) in the CAP group;
aspiration pneumonia (1) in group 1; aspiration pneumonia
(2), Gram-negative bacilli (2), atypical agents (2) and L. pneu-
mophila (1) in group 2; Gram-negative bacilli (3), atypical
agents (2) and aspiration pneumonia (1) in group 3; and
aspiration pneumonia (4), Gram-negative bacilli (2) and
atypical agents (2) in group 4.
Patients included in group 4 more frequently developed
in-hospital complications (Table 4). The duration of intra-
venous therapy was signiﬁcant longer in groups 2, 3 and 4,
and hospital stay was signiﬁcantly longer in groups 3 and 4.
TABLE 3. Aetiology by epidemiological group
Aetiology
CAP HCAP
Group 1a Group 2a Group 3a Group 4a
n = 1668,
no. (%)
n = 19,
no. (%) p
n = 198,
no. (%) p
n = 137,
no. (%) p
n = 131,
no. (%) p
Streptococcus pneumoniae 686 (41.1) 8 (42.1) 0.92 80 (40.4) 0.85 51 (37.2) 0.37 49 (37.4) 0.41
Bacteraemic pneumococcal pneumonia 175 (10.9) 1 (5.9) 1 23 (12) 0.66 9 (7) 0.16 12 (9.8) 0.68
Legionella pneumophila 111 (6.7) 0 (0) 0.63 5 (2.5) 0.02 1 (0.7) 0.003 1 (0.8) 0.007
Haemophilus inﬂuenzae 80 (4.8) 1 (5.3) 0.60 9 (4.5) 0.87 12 (8.8) 0.04 3 (2.3) 0.18
Aspiration pneumonia 91 (5.5) 3 (15.8) 0.08 18 (9.1) 0.03 13 (9.5) 0.05 37 (28.2) <0.001
Staphylococcus aureus 5 (0.3) 2 (10.2) 0.002 2 (1) 0.16 1 (0.7) 0.37 1 (0.8) 0.36
Atypical agents 81 (4.9) 0 (0) 1 5 (2.5) 0.13 6 (4.4) 0.80 3 (2.3) 0.18
Gram-negative bacilli 30 (1.8) 1 (5.3) 0.29 5 (2.5) 0.41 4 (2.9) 0.32 5 (3.9) 0.31
Bacteraemic Gram-negative bacilli
pneumonia
14 (0.8) 0 (0) 1 2 (1) 0.68 2 (1.5) 0.34 2 (1.5) 0.32
Pseudomonas aeruginosa 19 (1.1) 0 (0) 1 4 (2) 0.29 2 (1.5) 0.67 1 (0.8) 1
Bacteraemic Pseudomonas
aeruginosa pneumonia
5 (0.3) 0 (0) 1 2 (1) 0.16 1 (0.7) 0.37 0 (0) 1
Other aetiologies 32 (1.9) 0 (0) 1 1 (0.5) 0.24 1 (0.7) 0.50 2 (1.5) 1
Unknown aetiology 602 (36.2) 7 (36.8) 0.95 75 (38.1) 0.60 46 (33.8) 0.58 35 (26.7) 0.02
CAP, community-acquired pneumonia; HCAP, healthcare-associated CAP.
aGroup 1: received intravenous therapy at home; received wound care or specialized nursing care through a healthcare agency, family, or friends; or had self-administered
intravenous medical therapy in the 30 days before pneumonia (patients whose only home therapy was oxygen were excluded). Group 2: attended a hospital or haemodialysis
clinic or received intravenous chemotherapy in the 30 days before pneumonia. Group 3: admitted to an acute-care hospital for two or more days in the 90 days before pneu-
monia. Group 4: resided in a nursing home or long-term-care facility. p-Values show the differences between the HCAP and CAP groups.
TABLE 4. Initial antibiotic therapy and outcomes of pneumonia by epidemiological groupa
Therapy and outcomes
CAP HCAP
Group 1b Group 2b Group 3b Group 4b
n = 1668,
no. (%)
n = 19,
no. (%) p
n = 198,
no. (%) p
n = 137,
no. (%) p
n = 131,
no. (%) p
Monotherapy 974 (58.4) 14 (73.7) 0.17 108 (54.5) 0.30 88 (64.2) 0.18 87 (66.4) 0.07
b-Lactamsc 653 (39.1) 10 (52.6) 0.23 87 (43.9) 0.19 69 (50.4) 0.01 82 (62.6) <0.001
Levoﬂoxacin 296 (17.7) 4 (21.1) 0.70 20 (10.1) 0.007 14 (10.2) 0.02 5 (3.8) <0.001
Combination therapyd 691 (41.5) 5 (26.3) 0.18 89 (45.2) 0.32 49 (35.8) 0.19 44 (33.6) 0.07
b-Lactams + levoﬂoxacin 640 (38.4) 5 (26.3) 0.28 82 (41.4) 0.40 41 (29.9) 0.05 41 (31.3) 0.10
b-Lactams + macrolides 13 (0.8) 0 (0) 1 3 (1.5) 0.23 6 (4.4) 0.002 1 (0.8) 1
Inappropriate antibiotic therapy 66 (6.2) 1 (8.3) 0.54 7 (5.8) 0.86 6 (6.7) 0.84 8 (8.4) 0.40
In-hospital complications 561 (33.8) 7 (36.8) 0.77 65 (32.8) 0.79 53 (39) 0.21 55 (42) 0.05
ICU admission 179 (10.8) 1 (5.3) 0.71 18 (9.1) 0.46 14 (10.2) 0.83 8 (6.1) 0.09
Need for mechanical ventilation 140 (8.6) 2 (10.5) 0.67 17 (8.6) 0.99 11 (8.1) 0.86 6 (4.7) 0.13
Length of hospital stay (days) (median (IQR)) 8 (5–11) 7 (4–10) 0.27 8 (5–13) 0.58 9 (7–12) 0.001 9 (6–12) 0.02
Length of intravenous therapy (days) (mean (SD)) 5.5 (5.8) 5 (4.1) 0.72 6.7 (8.3) 0.04 6.6 (5.9) 0.02 6.7 (5.6) 0.02
Length of therapy (days) (mean (SD)) 13.5 (8.3) 10.7 (3.7) 0.33 13.3 (9.8) 0.73 12.9 (7.5) 0.46 12.8 (6.7) 0.65
Early case-fatality rate (<48 h) 25 (1.5) 1 (5.3) 0.25 6 (3) 0.13 1 (0.7) 0.71 5 (3.8) 0.06
Overall case-fatality rate (30 days) 90 (5.4) 2 (10.5) 0.27 18 (9.1) 0.03 10 (7.3) 0.34 26 (19.8) <0.001
CAP, community-acquired pneumonia; HCAP, healthcare-associated CAP; ICU, intensive-care unit; IQR, interquartile range; SD, standard deviation.
aData are given as numbers (percentages) except where otherwise indicated.
bGroup 1: received intravenous therapy at home; received wound care or specialized nursing care through a healthcare agency, family, or friends; or had self-administered
intravenous medical therapy in the 30 days before pneumonia (patients whose only home therapy was oxygen were excluded). Group 2: attended a hospital or haemodialysis
clinic or received intravenous chemotherapy in the 30 days before pneumonia. Group 3: admitted to an acute-care hospital for two or more days in the 90 days before pneu-
monia. Group 4: resided in a nursing home or long-term-care facility. p-Values show the differences between the HCAP and CAP groups.
cPatients treated with amoxycillin–clavulanate or ceftriaxone: CAP group, 642 patients; group 1, nine patients; group 2, 81 patients; group 3, 66 patients; group 4, 80 patients.
Patients treated with antipseudomonal b-lactams (piperacillin–tazobactam, imipenem, ceftazidime, cefepime): CAP group, 11 patients; group 1, one patient; group 2, six
patients; group 3, three patients; group 4, two patients.
dPatients treated with amoxicillin–clavulanate or ceftriaxone: CAP group, 670 patients; group 1, ﬁve patients; group 2, 82 patients; group 3, 41 patients; group 4, 40 patients.
Patients treated with antipseudomonal b-lactams (piperacillin–tazobactam, imipenem, ceftazidime, cefepime): CAP group, 10 patients; group 1, no patients; group 2, ﬁve
patients; group 3, ﬁve patients; group 4, three patients.
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The overall case-fatality rate was higher in patients with
HCAP than in patients with CAP (11.5% vs. 5.4%; p <0.001),
especially in groups 2 and 4. Causes of death were similar in
all groups. Respiratory failure was the most frequent cause
of death in all groups, followed by shock/multi-organ failure.
Among patients who received inappropriate initial empirical
therapy, seven died within 30 days of hospitalization, ﬁve in
the CAP group (four patients with P. aeruginosa and one
patient with Klebsiella pneumoniae), one in group 2 (P. aerugin-
osa), and one in group 4 (aspiration pneumonia). Causes of
death in these patients were acute respiratory failure (three
cases), shock/multi-organ failure (two cases), and cardiovas-
cular events (two cases).
Discussion
In this study, we found that S. pneumoniae was the most fre-
quent causative pathogen in all HCAP groups as well as in the
CAP group. Importantly, we documented a low incidence of
multidrug-resistant organisms. On the other hand, aspiration
pneumonia was frequent, especially among patients who
resided in a nursing home or long-term-care facility. This ﬁnd-
ing may be explained by the fact that these patients were
older and more often had cerebrovascular diseases and
impaired consciousness at presentation. Difﬁculty in swallow-
ing is relatively frequent among patients with these conditions,
and they are more prone to aspiration [16]. The rate of atypi-
cal pathogens in patients with HCAP was low, reinforcing the
concept that coverage of atypical pathogens in HCAP is not
routinely needed. Finally, L. pneumophila was more common in
patients with CAP, probably reﬂecting the fact that this popu-
lation is more frequently exposed to exogenous sources [17].
Our ﬁnding of a low incidence of multidrug-resistant
organisms markedly differs from those of previous studies,
mostly from the USA and Japan [3–5,18]. In these studies,
the number of pneumonias caused by methicillin-resistant
Staphylococcus aureus, P. aeruginosa and Enterobacteriaceae
with varying levels of resistance was unexpectedly high, even
in patients with CAP. In contrast, in a recent interesting
study of 150 consecutive cases of nursing home-acquired
pneumonia documented over a 10-year period, Polverino
et al. [19] found that S. pneumoniae was the most frequent
causative agent (58% of cases), whereas methicillin-resistant
Staphylococcus aureus and P. aeruginosa were less common
(three cases and two cases, respectively).
It is important to note that current data on the causative
organisms of HCAP in the USA is mainly reported by retro-
spective studies that have retrieved the information from a
database without the use of uniform criteria for distinguish-
ing colonization bacteria from pathogens [3–5,18]. Moreover,
the deﬁnition of HCAP included immunocompromised
patients in some studies [4,18]. On the other hand, the rele-
vance of aspiration pneumonia could have been underesti-
mated, because of the difﬁculties inherent in diagnosis.
Recognition of aspiration pneumonia requires a careful clini-
cal evaluation when macroscopic aspiration is not observed.
Moreover, the results of microbiological studies are often
negative, because the invasive procedures necessary to
obtain a reliable diagnosis are not usually performed. Con-
sequently, retrospective studies based on positive cultures
are not able to detect this entity.
Patients with HCAP commonly present a worse clinical
course than those with CAP, and a prolonged length of hos-
pital stay [2–5]. In our study, patients who attended a hospi-
tal or haemodialysis clinic or received intravenous
chemotherapy in the 30 days before pneumonia (group 2)
and those who resided in a nursing home or long-term-care
facility (group 4) had signiﬁcantly higher overall case-fatality
rates than the remaining patients (9.1% and 19.8%, respec-
tively). These two groups have the highest ages and the high-
est prevalence of comorbid conditions: cancer, chronic
cardiac disease, chronic renal disease, and, especially, cere-
brovascular disease and dementia. These patients have a
higher risk of aspiration pneumonia, which has been associ-
ated with poor clinical outcomes in a number of previous
studies [19–22].
Some studies have found that patients with HCAP are
more likely to receive inappropriate antimicrobial treatment
than patients with CAP [3–5]. In the present study, we did
not ﬁnd signiﬁcant differences regarding inappropriate initial
empirical therapy between the pneumonia groups. This fact
is probably related to the low frequency of multidrug-resis-
tant pathogens isolated in our study. Interestingly, we found
that the commonest type of pneumonia among patients with
HCAP receiving inappropriate initial empirical antibiotic ther-
apy was aspiration pneumonia. This ﬁnding concurs with that
of Polverino et al. [19], demonstrating that the lack of
aspiration assessment was a frequent cause of treatment
inadequacy.
Despite a number of strengths, our prospective observa-
tional study has certain limitations that should be acknowl-
edged. The research was performed at a single Spanish
institution, and the numbers of patients in some HCAP
groups were relatively small. Therefore, our results should
be interpreted with caution, as different causative organisms
and rates of antibiotic resistance may be encountered in
other countries. Finally, the rate of admission to the inten-
sive-care unit and the requirement for mechanical ventilation
was low. This might limit the applicability of our results.
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It should be noted, however, that HCAP patients are signiﬁ-
cantly older than CAP patients. In this regard, it has been
shown that elderly patients are less frequently admitted to
the intensive-care unit and less frequently undergo mechani-
cal ventilation, probably because of the disappointing progno-
sis (16).
In conclusion, our results highlight the heterogeneity of
patients included in the current concept of HCAP. Signiﬁ-
cantly, we documented a low frequency of multidrug-resis-
tant pathogens causing HCAP pneumonia in our area. Our
results argue in favour of individual evaluation of each
patient’s characteristics, and a targeted approach when
selecting initial empirical antibiotic therapy. Most patients
with HCAP may be treated in the same way as patients with
CAP, after carefully ruling out the presence of aspiration
pneumonia.
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